IL6 and non-small cell lung carcinoma: Mechanistically, FXR exerts its pro-metastatic effect by upregulating IL-6ST and IL-6 via direct transactivation, thereby leading to activation of the Jak2/STAT3 signaling pathway in NSCLC cells (Fig. 7).